1 / 6

Immunotherapy Drugs Market In-Depth Overview of Product Specification, Technology

Checkpoint inhibitors and vaccines are the two major types of immunotherapy drugs analyzed in the report. Of these, checkpoint inhibitors held a larger share in the immunotherapy drugs market, accounting for 66.3% in 2017. Checkpoint inhibitors are the first preference for the treatment of chronic diseases, as they provide better and effective treatment results. These drugs act directly on site of action, without delaying the effect of medicine, and are thus being highly adopted for the treatment of several diseases. Some of the major checkpoint inhibitors brand available in the market are Humira, Rituxan/MabThera, Herceptin, Remicade, and Enbrel.<br>Based on therapy area, the immunotherapy drugs market has been categorized into cancer, autoimmune and inflammatory diseases, and infectious diseases. Of these, autoimmune and inflammatory diseases is expected to be the fastest growing category, at a CAGR of 14.8% during the forecast period.<br>

psmarketresearch2017
Download Presentation

Immunotherapy Drugs Market In-Depth Overview of Product Specification, Technology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Immunotherapy Drugs Market Size to Reach $227.6 Billion by 2023

  2. Surge in the prevalence of chronic diseases, and thriving demand and development of monoclonal antibodies (mAbs) are the key factors driving the market growth. Checkpoint inhibitors and vaccines are the two major types of immunotherapy drugs analyzed in the report. Of these, checkpoint inhibitors held a larger share in the immunotherapy drugs market, accounting for 66.3% in 2017. Checkpoint inhibitors are the first preference for the treatment of chronic diseases, as they provide better and effective treatment results. These drugs act directly on site of action, without delaying the effect of medicine, and are thus being highly adopted for the treatment of several diseases. Some of the major checkpoint inhibitors brand available in the market are Humira, Rituxan/MabThera, Herceptin, Remicade, and Enbrel. Access Detailed Report Summary at: https://www.psmarketresearch.com/market-analysis/immunotherapy-drugs-market “

  3. Globally, the rising prevalence of chronic diseases is a major healthcare burden that effects high income nations as well as low and middle-income countries (LMIC). The impact of these diseases can be ascertained from the fact that cancer is estimated to lead to 9.6 million deaths in 2018, as reported by the World Health Organisation (WHO). The organisation further stated that around 70% of deaths from cancer occur in LMIC. Download Report Sample at: https://www.psmarketresearch.com/market-analysis/immunotherapy-drugs-market/report-sample “

  4. The report provides epidemiology analysis for cancer, autoimmune and inflammatory diseases, and infectious diseases. According to the International Agency for Research on Cancer (IARC) in 2018, 18.1 million people are estimated to be suffering from cancer globally, which is expected to reach 29.5 million by 2040. Another study conducted by the American Medical Association (AMA) between 2005–2015, reported that the incident of cancer cases increased by 33% during this period, of which 16.4% of the cases were due to aging population. Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=immunotherapy-drugs-market “

  5. Similarly, in April 2018, Pfizer Inc. and Allogene Therapeutics Inc. entered into an asset contribution agreement to use Pfizer’s portfolio related to allogeneic CAR-T therapy, an investigational immune cell therapy, for cancer. This agreement acted as an attractive opportunity for Pfizer Inc. to continue the development of CAR-T therapy. Some of the other leading players operating in the global immunotherapy drugs market are F. Hoffmann-La Roche Ltd., AbbVie Inc., AstraZeneca PLC, Merck & Co. Inc., GlaxoSmithKline plc, Novartis International AG, Johnson & Johnson, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Sanofi, Medigene AG, C. H. Boehringer Sohn AG & Co. KG, Takeda Pharmaceutical Company Limited, and Celgene Corporation. “

  6. THANK YOU! For queries, kindly write to: enquiry@psmarketresearch.com GET IN TOUCH www.psmarketresearch.com B-13, Sector-2, Noida, U.P.-201301, INDIA Contact No: +91 120 4541 337 US/Canada Toll-Free: 1-888-778-7886 US/Canada Toll-Free: 1-888-778-7886

More Related